Citations 1

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Blood Advances | March 26, 2024 | Volume: 8 | Issue: 10 | Pages: 2400-2404

10.1182/bloodadvances.2023011030 | PMID 38531062